Reply: Insurance should cover vancomycin for primary sclerosing cholangitis

Christopher L. Bowlus; Lionel Arrivé; Annika Bergquist; Mark Deneau; Lisa Forman; Sumera I. Ilyas; Keri E. Lunsford; Mercedes Martinez; Gonzalo Sapisochin; Rachna Shroff; James H. Tabibian; David N. Assis

doi:10.1097/HEP.0000000000000305

Reply: Insurance should cover vancomycin for primary sclerosing cholangitis

Christopher L. Bowlus, Lionel Arrivé, Annika Bergquist, Mark Deneau, Lisa Forman, Sumera I. Ilyas, Keri E. Lunsford, Mercedes Martinez, Gonzalo Sapisochin, Rachna Shroff, James H. Tabibian, David N. Assis

Medicine

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	E176-E177
Journal	Hepatology
Volume	77
Issue number	6
DOIs	https://doi.org/10.1097/HEP.0000000000000305
State	Published - Jun 2023

ASJC Scopus subject areas

Hepatology

Access to Document

10.1097/HEP.0000000000000305

Cite this

@article{3fc7e26277204a2e8128f58530c205e2,

title = "Reply: Insurance should cover vancomycin for primary sclerosing cholangitis",

author = "Bowlus, {Christopher L.} and Lionel Arriv{\'e} and Annika Bergquist and Mark Deneau and Lisa Forman and Ilyas, {Sumera I.} and Lunsford, {Keri E.} and Mercedes Martinez and Gonzalo Sapisochin and Rachna Shroff and Tabibian, {James H.} and Assis, {David N.}",

note = "Funding Information: Christopher L. Bowlus consults for and received grants from Cymabay and Ipsen. He received grants from Gilead, BMS, GSK, Novartis, PLIANT, Chemomab, and Intercept. Annika Bergquist received grants from Gilead. Mark Deneau consults for Gilead and Hightide Biopharmaceuticals. Keri E. Lunsford owns stock in ROMTech. She consults for GATT Technologies. Rachna Shroff consults for Syros. She advises AstraZeneca, B{\"o}hringer Ingelheim Pharm., Clovis, Genentech, Incyte, Merck, QED Therapeutics, Servier, Tacho, and Zymeworks. She received grants from Bayer, BMS, Exelixis Pharm., IMV Inc., LOXO, Novocure, NUCANA, Pieris, QED Therapeutics, Rafael Pharm., Seagen, and Taiho. James H. Tabibian consults for Olympus and Horizon. David N. Assis received grants from Gilead. The remaining authors have no conflicts to report.",

year = "2023",

month = jun,

doi = "10.1097/HEP.0000000000000305",

language = "English (US)",

volume = "77",

pages = "E176--E177",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Ltd",

number = "6",

}

TY - JOUR

T1 - Reply

T2 - Insurance should cover vancomycin for primary sclerosing cholangitis

AU - Bowlus, Christopher L.

AU - Arrivé, Lionel

AU - Bergquist, Annika

AU - Deneau, Mark

AU - Forman, Lisa

AU - Ilyas, Sumera I.

AU - Lunsford, Keri E.

AU - Martinez, Mercedes

AU - Sapisochin, Gonzalo

AU - Shroff, Rachna

AU - Tabibian, James H.

AU - Assis, David N.

N1 - Funding Information: Christopher L. Bowlus consults for and received grants from Cymabay and Ipsen. He received grants from Gilead, BMS, GSK, Novartis, PLIANT, Chemomab, and Intercept. Annika Bergquist received grants from Gilead. Mark Deneau consults for Gilead and Hightide Biopharmaceuticals. Keri E. Lunsford owns stock in ROMTech. She consults for GATT Technologies. Rachna Shroff consults for Syros. She advises AstraZeneca, Böhringer Ingelheim Pharm., Clovis, Genentech, Incyte, Merck, QED Therapeutics, Servier, Tacho, and Zymeworks. She received grants from Bayer, BMS, Exelixis Pharm., IMV Inc., LOXO, Novocure, NUCANA, Pieris, QED Therapeutics, Rafael Pharm., Seagen, and Taiho. James H. Tabibian consults for Olympus and Horizon. David N. Assis received grants from Gilead. The remaining authors have no conflicts to report.

PY - 2023/6

Y1 - 2023/6

UR - http://www.scopus.com/inward/record.url?scp=85159741216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85159741216&partnerID=8YFLogxK

U2 - 10.1097/HEP.0000000000000305

DO - 10.1097/HEP.0000000000000305

M3 - Letter

C2 - 36695291

SN - 0270-9139

VL - 77

SP - E176-E177

JO - Hepatology

JF - Hepatology

IS - 6

ER -

Reply: Insurance should cover vancomycin for primary sclerosing cholangitis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this